{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:39:24Z","timestamp":1792712364797,"version":"4.5.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Knee Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for glycemic control and weight management, but their association with postoperative thrombotic events after total knee arthroplasty (TKA) remains unclear. We performed a retrospective cohort study using de-identified data from the TriNetX United States Collaborative Network, including adults who underwent primary TKA between December 1, 2006, and June 1, 2025. Patients with prior myocardial infarction (MI), deep vein thrombosis (DVT), venous thromboembolism (VTE), or pulmonary embolism (PE) were excluded. Exposure was defined as a prescription for a GLP-1 RA within 1 year and 1 day before surgery. A 1:1 propensity score match was performed on demographics, relevant comorbidities, and medications, yielding 11,765 patients in each cohort. Outcomes were postoperative MI, DVT, VTE, and PE. Compared with matched controls, patients prescribed GLP-1 RAs had a significantly lower risk of MI (25\/11,246 vs. 47\/11,171; risk ratio [RR] 0.528; 95% confidence interval [CI], 0.325\u20130.858). GLP-1 RAs use was also associated with a reduced risk of DVT (74\/11,319 vs. 103\/11,308; RR 0.718; 95% CI, 0.533\u20130.966) and VTE (133\/11,040 vs. 172\/11,027; RR 0.772; 95% CI, 0.617\u20130.967). In contrast, no statistically significant difference was observed in the incidence of PE between groups (49\/11,352 vs. 58\/11,382; RR 0.847; 95% CI, 0.580\u20131.238). Overall, preoperative GLP-1 RA use was associated with a significantly lower postoperative risk of MI, DVT, and VTE following TKA in this large, nationally representative cohort.<\/jats:p>","DOI":"10.1055\/a-2982-7440","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:58:31Z","timestamp":1792105111000},"source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonist Use before Total Knee Arthroplasty is Associated with Lower Postoperative MI, DVT, and VTE Rates"],"prefix":"10.1055","author":[{"given":"Bryan","family":"Yavari","sequence":"additional","affiliation":[{"name":"The University of Arizona College of Medicine - Phoenix, and Banner University Medical Center Phoenix, Arizona, United States","place":["Phoenix"],"department":["Department of Orthopedic Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria","family":"Soltankhah","sequence":"additional","affiliation":[{"name":"The University of Arizona College of Medicine - Phoenix, and Banner University Medical Center Phoenix, Arizona, United States","place":["Phoenix"],"department":["Department of Orthopedic Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafis","family":"Eghrari","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center, Texas, United States","place":["Dallas"],"department":["Department of Physical Medicine and Rehabilitation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanna","family":"Calderon","sequence":"additional","affiliation":[{"name":"The University of Arizona College of Medicine - Phoenix, and Banner University Medical Center Phoenix, Arizona, United States","place":["Phoenix"],"department":["Department of Orthopedic Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Lederman","sequence":"additional","affiliation":[{"name":"The University of Arizona College of Medicine - Phoenix, and Banner University Medical Center Phoenix, Arizona, United States","place":["Phoenix"],"department":["Department of Orthopedic Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Shah","sequence":"additional","affiliation":[{"name":"The University of Arizona College of Medicine - Phoenix, and Banner University Medical Center Phoenix, Arizona, United States","place":["Phoenix"],"department":["Department of Orthopedic Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization Guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"F Celletti","year":"2026","journal-title":"JAMA"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: A scientific statement from the American Heart Association","volume":"145","author":"J J Joseph","year":"2022","journal-title":"Circulation"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ajcnut.2023.07.007","article-title":"GLP-1 receptor agonists for weight loss in people without type 2 diabetes: what is the current evidence?","volume":"118","author":"L L Gluud","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"102782","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"N Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"16","key":"ref7","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jacc.2020.02.056","article-title":"Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC Focus Seminar","volume":"75","author":"T Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"35","key":"ref8","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"41","author":"F Marsico","year":"2020","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2021.08.015","article-title":"Pulmonary embolism and deep vein thrombosis: similar but different","volume":"206","author":"N Wenger","year":"2021","journal-title":"Thromb Res"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/bloodadvances.2025015871","article-title":"Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation","volume":"9","author":"C H Chiang","year":"2025","journal-title":"Blood Adv"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11883-025-01350-7","article-title":"Current perspectives on GLP-1 agonists in contemporary clinical practice from science and mechanistic foundations to optimal translation","volume":"27","author":"H Abu-Nejim","year":"2025","journal-title":"Curr Atheroscler Rep"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"B Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db14-0976","article-title":"Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans","volume":"64","author":"J Koska","year":"2015","journal-title":"Diabetes"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/db15-1141","article-title":"Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis","volume":"65","author":"A Cameron-Vendrig","year":"2016","journal-title":"Diabetes"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1161\/ATVBAHA.119.313645","article-title":"Native, intact glucagon-like peptide 1 is a natural suppressor of thrombus growth under physiological flow conditions","volume":"40","author":"M Sternkopf","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","author":"I Ros-Madrid","year":"2025","journal-title":"Can J Physiol Pharmacol"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1111\/dom.16366","article-title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis","volume":"27","author":"Y Ren","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"152822","DOI":"10.1016\/j.bbrc.2025.152822","article-title":"GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance","volume":"789","author":"M A Ngabea","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1677\/JOE-08-0468","article-title":"A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules","volume":"201","author":"H Liu","year":"2009","journal-title":"J Endocrinol"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"e039446","DOI":"10.1161\/JAHA.124.039446","article-title":"Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Y Liu","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1016\/j.jtha.2025.06.020","article-title":"Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"C H Chiang","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474086.2025.2562077","article-title":"Impact of weight status on risk of venous thromboembolism associated with GLP-1 receptor agonists","volume":"18","author":"C H Chiang","year":"2025","journal-title":"Expert Rev Hematol"},{"issue":"03","key":"ref23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/wjs.12484","article-title":"Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist on Outcomes Following Major Surgery","volume":"49","author":"Z Rashid","year":"2025","journal-title":"World J Surg"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2106\/JBJS.24.00468","article-title":"Glucagon-like peptide-1 receptor agonists decrease medical and surgical complications in morbidly obese patients undergoing primary TKA","volume":"107","author":"B I Kim","year":"2025","journal-title":"J Bone Joint Surg Am"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1177\/21925682251391693","article-title":"Association between preoperative GLP-1 receptor analog use and postoperative complications and mortality following lumbar fusion surgery","volume":"16","author":"A A Kesaria","year":"2026","journal-title":"Global Spine J"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.arth.2025.09.054","article-title":"The impact of glucagon-like peptide-1 receptor agonist use on clinical outcomes after total hip and knee arthroplasty: a systematic review and meta-analysis of 346,899 patients","volume":"41","author":"S Lee","year":"2026","journal-title":"J Arthroplasty"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1016\/j.arth.2025.07.015","article-title":"Impact of glucagon-like peptide-1 receptor agonists on postoperative outcomes in arthroplasty: a systematic review","volume":"40","author":"V Lee","year":"2025","journal-title":"J Arthroplasty"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12933-025-02840-3","article-title":"Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety","volume":"24","author":"A SP Tang","year":"2025","journal-title":"Cardiovasc Diabetol"}],"container-title":["The Journal of Knee Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2982-7440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:03:07Z","timestamp":1792710187000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2982-7440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1055\/a-2982-7440","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1538-8506","1938-2480"],"issn-type":[{"value":"1538-8506","type":"print"},{"value":"1938-2480","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,10,15]]}}}